Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2Recruiting 2Completed 2Active not recruiting 2Withdrawn 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 41Lung Neoplasms 13Neoplasms 6Neoplasm Metastasis 4Thoracic Neoplasms 2Noonan Syndrome 2NSCLC 2Meningeal Carcinomatosis 2Colorectal Neoplasms 2Carcinoma, Squamous Cell 2Brain Neoplasms 2Adenocarcinoma of Lung 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1T790M Positive NSCLC Patients 1Solid Tumor 1Skin Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Renal Insufficiency 1Progression Free Survival 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non Small Cell Lung Cancer Metastatic 1Neoplasms, Squamous Cell 1Neoplasms by Site 1Lung Diseases 1Locally Advanced or Metastatic EGFR T790M+ NSCLC 1Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer 1

Interventions

osimertinib 2Vinorelbine 2Pemetrexed 2Liquid Biopsy 2HMPL-013 2Gefitinib 2Carboplatin 2tislelizumab 1sulindac sulfone 1rezivertinib 1pembrolizumab 1anlotinib 1Radiotherapy 1Platinum 1Paclitaxel 1Gemcitabine 1Cisplatin 1Cetuximab 1CP protocol 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × NSCLC × osimertinib × Clear all
NCT03810066 2024-05-09

Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)

University Hospital, Essen

Phase 2 Completed
16 enrolled
Thoracic

NSCLC

NCT03394118 2021-04-27

TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy

Asan Medical Center

Phase 2 Completed
63 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡